BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

500672

NOVARTIND

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

NOVARTIS INDIA LTD. Share Price Update

As of the latest trading session, NOVARTIS INDIA LTD. share price is currently at ₹ 765.8, which is down by ₹ -5.65 from its previous closing. Today, the stock has fluctuated between ₹ 747.60 and ₹ 783.20. Over the past year, NOVARTIS INDIA LTD. has achieved a return of -26.70 %. In the last month alone, the return has been -4.48 %. Read More...

NOVARTIS INDIA LTD. fundamentals


  • Market cap (Cr)

  • P/E Ratio (TTM)

  • Beta

  • Book Value / share

  • Return on equity

    %

  • EPS (TTM)

  • Dividend yield

    %

  • Net profit/quarter (Cr)

info icon alternate text
  • Market cap (Cr)

    1,890.80

  • P/E Ratio (TTM)

    21.92

  • Beta

    0.54

  • Book Value / share

    295.35

  • Return on equity

    11.21%

  • EPS (TTM)

    34.94

  • Dividend yield

    %

  • Net profit/quarter (Cr)

    25.45

info icon alternate text

NOVARTIS INDIA LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 93.00
Operating Expense 68.31
Net Profit 25.45
Net Profit Margin (%) 27.36
Earnings Per Share (EPS) 10.31
EBITDA 36.18
Effective Tax Rate (%) 27.88
Particulars SEP 2024 (Values in Cr)
Revenue 87.11
Operating Expense 69.87
Net Profit 20.41
Net Profit Margin (%) 23.43
Earnings Per Share (EPS) 8.27
EBITDA 28.29
Effective Tax Rate (%) 25.94
Particulars JUN 2024 (Values in Cr)
Revenue 92.29
Operating Expense 69.02
Net Profit 25.74
Net Profit Margin (%) 27.89
Earnings Per Share (EPS) 10.42
EBITDA 34.37
Effective Tax Rate (%) 23.57
Particulars MAR 2024 (Values in Cr)
Revenue 81.17
Operating Expense 70.25
Net Profit 14.68
Net Profit Margin (%) 18.08
Earnings Per Share (EPS) 5.95
EBITDA 21.63
Effective Tax Rate (%) 31.17
Particulars DEC 2023 (Values in Cr)
Revenue 84.54
Operating Expense 65.19
Net Profit 26.57
Net Profit Margin (%) 31.42
Earnings Per Share (EPS) 10.76
EBITDA 41.73
Effective Tax Rate (%) 35.68
Particulars MAR 2024 (Values in Cr)
Revenue 335.07
Operating Expense 273.91
Net Profit 85.19
Net Profit Margin (%) 25.42
Earnings Per Share (EPS) 34.50
EBITDA 126.94
Effective Tax Rate (%) 30.64
Particulars MAR 2023 (Values in Cr)
Revenue 378.74
Operating Expense 321.47
Net Profit 103.36
Net Profit Margin (%) 27.29
Earnings Per Share (EPS) 41.86
EBITDA 123.19
Effective Tax Rate (%) 10.41
Particulars MAR 2022 (Values in Cr)
Revenue 399.87
Operating Expense 387.24
Net Profit -3.72
Net Profit Margin (%) -0.93
Earnings Per Share (EPS) -1.51
EBITDA 10.66
Effective Tax Rate (%) 2.61
Particulars MAR 2021 (Values in Cr)
Revenue 381.35
Operating Expense 374.40
Net Profit 20.90
Net Profit Margin (%) 5.48
Earnings Per Share (EPS) 8.46
EBITDA 59.87
Effective Tax Rate (%) 47.80
Particulars MAR 2020 (Values in Cr)
Revenue 438.25
Operating Expense 445.75
Net Profit 10.08
Net Profit Margin (%) 2.30
Earnings Per Share (EPS) 4.08
EBITDA 48.17
Effective Tax Rate (%) 64.80
Particulars MAR 2024 (Values in Cr)
Book Value / Share 301.79
ROE % 11.21
ROCE % 15.57
Total Debt to Total Equity 0.02
EBITDA Margin 37.88
Particulars MAR 2023 (Values in Cr)
Book Value / Share 314.29
ROE % 14.09
ROCE % 14.88
Total Debt to Total Equity 0.03
EBITDA Margin 32.53
Particulars MAR 2022 (Values in Cr)
Book Value / Share 280.27
ROE % 5.84
ROCE % 5.66
Total Debt to Total Equity 0.06
EBITDA Margin 13.75
Particulars MAR 2021 (Values in Cr)
Book Value / Share 288.16
ROE % 2.92
ROCE % 5.57
Total Debt to Total Equity 0.09
EBITDA Margin 15.70
Particulars MAR 2020 (Values in Cr)
Book Value / Share 292.03
ROE % 1.36
ROCE % 4.24
Total Debt to Total Equity 0.05
EBITDA Margin 10.99
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 596.08
Total Assets 924.93
Total Liabilities 924.93
Total Equity 744.82
Share Outstanding 24690797
Price to Book Ratio 3.41
Return on Assets (%) 9.21
Return on Capital (%) 11.44
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 555.94
Total Assets 982.94
Total Liabilities 982.94
Total Equity 775.66
Share Outstanding 24690797
Price to Book Ratio 1.80
Return on Assets (%) 10.51
Return on Capital (%) 13.33
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 517.63
Total Assets 957.57
Total Liabilities 957.57
Total Equity 691.70
Share Outstanding 24690797
Price to Book Ratio 2.11
Return on Assets (%) -0.38
Return on Capital (%) -0.54
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 498.88
Total Assets 1002.29
Total Liabilities 1002.29
Total Equity 711.19
Share Outstanding 24690797
Price to Book Ratio 1.92
Return on Assets (%) 2.08
Return on Capital (%) 2.94
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 581.91
Total Assets 1077.64
Total Liabilities 1077.64
Total Equity 720.73
Share Outstanding 24690797
Price to Book Ratio 1.72
Return on Assets (%) 0.93
Return on Capital (%) 1.4
Particulars MAR 2024 (Values in Cr)
Net Income 122.84
Cash from Operations 75.13
Cash from Investing 33.13
Cash from Financing -120.99
Net change in Cash 25.54
Free Cash Flow 75.13
Particulars MAR 2023 (Values in Cr)
Net Income 115.38
Cash from Operations 42.46
Cash from Investing -153.25
Cash from Financing -30.48
Net change in Cash -138.93
Free Cash Flow 42.77
Particulars MAR 2022 (Values in Cr)
Net Income -3.82
Cash from Operations 57.26
Cash from Investing 87.04
Cash from Financing -35.63
Net change in Cash 90.08
Free Cash Flow 57.76
Particulars MAR 2021 (Values in Cr)
Net Income 40.04
Cash from Operations -34.02
Cash from Investing 95.16
Cash from Financing -36.80
Net change in Cash -10.85
Free Cash Flow -33.93
Particulars MAR 2020 (Values in Cr)
Net Income 28.64
Cash from Operations 14.99
Cash from Investing 55.91
Cash from Financing -41.41
Net change in Cash -8.64
Free Cash Flow 15.99
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.10 19.95 2.02 284.31 34.11 / 77.70
BLISS GVS PHARMA LTD 122.65 16.07 1.27 1292.37 92.25 / 184.95
CIPLA LTD 1541.00 24.94 4.38 124457.39 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 272.25 22.56 2.76 801.26 145.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 2904.45 57.61 29.41 49203.14 1924.30 / 3147.45
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 37.10 22.35 6.30 284.31 34.11 / 77.70
AMRUTAJAN HEALTH LTD 679.10 39.81 6.59 1963.32 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8795.90 131.18 32.36 21989.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 122.65 15.93 1.26 1292.37 92.25 / 184.95

NOVARTIS INDIA LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
765.80 -0.73 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 789.00
  • 26 Days 805.30
  • 10 Days 799.80
  • 50 Days 818.80
  • 12 Days 801.40
  • 100 Days 863.80
  • 20 Days 803.90
  • 200 Days 914.20
781.18 PIVOT

First Support

753.57

First Resistance

799.07

Second Support

735.68

Second Resistance

826.68

Third Support

708.07

Third Resistance

844.57

RSI

38.67

ADX

21.16

MACD

-0.55

Williams % R

-91.06

Commodity Channel Index (CCI)

-123.90

Date

2025-04-29

Week

11901.00

Same Day

18487.00

Month

6772.00

1 Year

0.55

3 Year

0.45

Over 1 Month

-4.48%

down

Over 1 Year

-26.70%

down

Over 3 Months

-13.02%

down

Over 3 Years

7.06%

down

Over 6 Months

-26.96%

down

Over 5 Years

3.95%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

NOVARTIS INDIA LTD. shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
28.6%
Promoter Holdings
70.67%
FII
0.18%
DII
0.53%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Novartis Ag 1.745068E7 (70.68%) Shareholding of Promoter and Promoter Group
Atul Limited 374627.0 (1.52%) Public Shareholding

News

Left Arrow
Right Arrow

NOVARTIS INDIA LTD. corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
20 Jul 2023 10.0 Final 21 Jul 2023 Equity shares
20 Jul 2023 37.5 Special 21 Jul 2023 Equity shares
20 Jul 2022 10.0 Final 22 Jul 2022 Equity shares
17 Aug 2021 10.0 Final 20 Aug 2021 Equity shares
29 Jul 2020 10.0 Final 31 Jul 2020 Equity shares
31 Jul 2019 10.0 Final 02 Aug 2019 Equity shares
18 Jul 2018 10.0 Final 20 Jul 2018 Equity shares
19 Jul 2017 10.0 Final 21 Jul 2017 Equity shares
21 Jul 2016 10.0 Final 22 Jul 2016 Equity shares
14 Jul 2015 10.0 Final 16 Jul 2015 Equity shares
16 Jul 2014 5.0 Final 18 Jul 2014 Equity shares
16 Jul 2013 10.0 Final 18 Jul 2013 Equity shares
18 Jul 2012 10.0 Final 20 Jul 2012 Equity shares
18 Jul 2011 10.0 Final 20 Jul 2011 Equity shares
21 Jul 2010 10.0 Final 23 Jul 2010 Equity shares
08 Jul 2009 10.0 Final 10 Jul 2009 Equity shares
07 Jul 2008 10.0 Final 09 Jul 2008 Equity shares
22 Mar 2007 10.0 Final 23 Mar 2007 Equity shares
20 Jul 2005 0.0 Final 22 Jul 2005 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

NOVARTIS INDIA LTD. Share Price

Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the world's second largest pharmaceutical company was incorporated on 13 December 1947. The Company is engaged in manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare; it operates into four segments such as Pharmaceuticals, Generics, Over the Trade Counter and Animal Health.

The origin of Novartis is linked to the origin of three distinct companies namely Geigy, Ciba, and Sandoz. The history of Geigy goes back to the middle of the 18th century, Ciba was founded around 1860, and Sandoz was set-up in 1886. In 1970 Ciba and Geigy merged to form Ciba-Geigy Ltd. Sandoz and Ciba-Geigy Ltd continued as separate entities for the next 25 years. In 1996, in one of the largest corporate mergers in history Sandoz and Ciba-Geigy Ltd. joined to form Novartis. In the year 1998, the company had set-up the Novartis Institute for Functional Genomics.

During the year 2000, Novartis acquired the products Famvir and Vectavir/Denavir from SmithKline Beecham also in the same year, the company started to provide treatment to leprosy patients worldwide through World Health Organisation (WHO). Also in 2000, NIL had started JEET (Joint Effort to Eradicate Tuberculosis) with the aim of increasing awareness among TB patents and to involve doctors more actively in the fight against disease. After a year, Novartis Respiratory Research Centre, the largest of its kind in the world, was opened in Horsham (UK) in 2001 and also during the same year Novartis had entered into a partnership with the WHO to stem the spread of malaria in areas of the world were the diseases in endemic.

The Glivec, a drug was launched by the company in April of the year 2002 in India. The Company bagged TERI corporate social responsibility award for the year 2002-03. Novartis united its generics businesses under one single global brand in the name of Sandoz during the year 2003 and also in the same year, the company was granted Exclusive Marketing Rights (EMR) for Glivec. In the year of 2005, the company and Astex Therapeutics formed an alliance to focus on novel cell cycle anti-cancer drugs and also NIL had debuted Citro-macalvit & Trioptal as new products for the year.

During the year 2006 alone Novartis had spent about USD 755 million on research into neglected diseases and various patient-access programs. In August of the same year 2006, the company had filed a petition in the Madras High Court challenging the rejection of the Glivec patent and the same petition was dismissed by the Madras high court in August of the year 2007. In the identical year of 2007, NIL sold its Medical Nutrition business to Nestle. The Company had launched a new marketing initiative on National scale in September of the year 2008 named Arogya Parivar targeting the healthcare needs of villagers.

New products and line extensions introduced during the period 2009-10 were Relmus , Coderan for Pain & Inflammation, Vinlep for Epilepsy and Givec HGC 100 mg for Oncology. Otrivin was re-launched as an OTC remedy in a new spray format and positioned as a convenient alternative to tablets.

During the period 2013-14, the Company signed a Distribution Agreement with Nutri-Ad International NV, Belgium, for marketing and distribution of their poultry feed supplements in India and started distributing Adimix 30 Coated, Eurotiox 32 Premix, Salmonil Dry, Toxynil Dry and Nutrilac IGA. The Company also signed a Marketing and Distribution Agreement with Johnson and Johnson Limited, India, for marketing and distribution of their Ethicon sutures under the brand names Mersutures Catgut 1, Ethilon Nylon and Mersilk Silk for veterinary use in the cattle and canine segments.

The Company launched Voveran maxxgel TM and a new version of Voveran@1ml in 2019,

Parent organization MNC Associate
NSE symbol NOVARTIND
Founded 1947
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Novartis India Ltd?

Answer Field

The share price of Novartis India Ltd for NSE is ₹ 672.25 and for BSE is ₹ 765.80.

What is the Market Cap of Novartis India Ltd?

Answer Field

The market cap of Novartis India Ltd for NSE is ₹ 0.0 Cr. and for BSE is ₹ 18,90.80 Cr. as of now.

What is the 52 Week High and Low of Novartis India Ltd?

Answer Field

The 52 Week High and Low of Novartis India Ltd for NSE is ₹ 698.20 and ₹ 0.00 and for BSE is ₹ 1248.00 and ₹ 744.95.

How to Buy Novartis India Ltd share?

Answer Field

You can trade in Novartis India Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Novartis India Ltd?

Answer Field

The 1 year returns on the stock has been -26.01%.

What is the Current Share Price of Novartis India Ltd?

Answer Field

Novartis India Ltd share price is for NSE ₹ 672.25 & for BSE ₹ 765.80 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Novartis India Ltd Share?

Answer Field

The market cap of Novartis India Ltd for NSE ₹ 0.0 & for BSE ₹ 18,90.80 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Novartis India Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Novartis India Ltd share is 21.92.

What is the PB ratio of Novartis India Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Novartis India Ltd share is 295.35.

How to Buy Novartis India Ltd Share?

Answer Field

You can trade in Novartis India Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Novartis India Ltd Share on Bajaj Broking App?

Answer Field

To buy Novartis India Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Novartis India Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|